Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.50% | 147.23 | 0.6% | $1189.34m | |
| MRK | Merck & Co., Inc. | 1.19% | 78.03 | 0.6% | $1026.59m | |
| PFE | Pfizer Inc. | 0.36% | 44.17 | 0.9% | $1005.85m | |
| ABBV | AbbVie, Inc. | 0.51% | 88.62 | 2.2% | $564.83m | |
| LLY | Eli Lilly and Company | -0.11% | 114.37 | 1.0% | $515.63m | |
| BMY | Bristol-Myers Squibb Company | 2.00% | 53.48 | 1.4% | $473.92m | |
| NVS | Novartis AG Sponsored ADR | 1.07% | 88.15 | 0.2% | $230.45m | |
| AZN | AstraZeneca PLC Sponsored ADR | 0.65% | 38.91 | 1.3% | $213.76m | |
| GSK | GlaxoSmithKline plc Sponsored ADR | 0.83% | 37.67 | 0.2% | $149.91m | |
| NVO | Novo Nordisk A/S Sponsored ADR Class B | 1.77% | 46.00 | 0.1% | $65.94m | |
| SNY | Sanofi Sponsored ADR | 1.85% | 45.14 | 0.2% | $46.70m | |
| LCI | Lannett Company, Inc. | -0.19% | 5.26 | 37.0% | $9.76m | |
| AKTX | Akari Therapeutics Plc Sponsored ADR | -0.84% | 1.80 | 1.7% | $0.03m | |
| EPIX | ESSA Pharma Inc | 1.60% | 2.54 | 0.1% | $0.00m |
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX). It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP). The company was founded on November 10, 2014 and is headquartered in New York, NY.